Finasteride vs. Dutasteride for Hair Loss: Efficacy, Side Effects, and Cost
Medically reviewed by [Reviewer Name, MD, Dermatology] | Last reviewed: August 2026 | Editorial policy | Sources
Finasteride and dutasteride are both 5-alpha-reductase inhibitors used for male androgenetic alopecia, but they differ in a critical way: finasteride selectively inhibits only Type II 5-alpha-reductase, while dutasteride inhibits both Type I and Type II — producing more complete DHT suppression. Dutasteride is FDA-approved only for BPH; its use for AGA is off-label in the US, but it is approved for AGA in Japan (2015) and South Korea (2009).
Head-to-Head Comparison
| Finasteride 1 mg | Dutasteride 0.5 mg | |
|---|---|---|
| 5-AR isoforms inhibited | Type II only | Type I and Type II (dual) |
| Serum DHT suppression | ~65–70% | ~90–95% |
| Scalp DHT suppression | ~64% | ~79% |
| FDA approval for AGA | Yes (1997) | No (off-label in US) |
| FDA approval for BPH | Yes (1992) | Yes (2001) |
| AGA-specific approval outside US | — | Japan (2015), South Korea (2009) |
| Evidence base for AGA | 25+ years; multiple large RCTs | Several RCTs; largest is Olsen 2006, n=416 |
| Hair count improvement vs. finasteride | Reference | Numerically superior in head-to-head trials |
| Plasma half-life | 6–8 hours | ~5 weeks (much longer) |
| Monthly cost (generic) | $15–$35 | $30–$60 (less available in 0.5 mg; often sourced as BPH dose) |
| Sexual side effect risk | ~1–2% excess over placebo | Likely slightly higher due to greater DHT suppression |
Efficacy Evidence: Does Dutasteride Work Better?
The most rigorous head-to-head comparison is the Olsen et al. 2006 randomized trial (n=416 men with AGA; 24 weeks): dutasteride 0.5 mg produced statistically significantly greater hair growth than finasteride 1 mg in terms of total hair count and hair weight. The dutasteride group showed approximately 12–13 hairs/cm² improvement vs. ~7 hairs/cm² for finasteride at 24 weeks — about 60–70% more growth.
A 2018 meta-analysis by Gubelin Harcha et al. synthesizing available RCT data similarly found dutasteride 0.5 mg to be superior to finasteride 1 mg in hair count outcomes, with statistical significance.
Which Should You Choose?
| Scenario | Consider |
|---|---|
| First-line AGA treatment; want FDA-approved option | Finasteride 1 mg |
| Partial or inadequate response to finasteride after 12–18 months | Physician discussion about switching to dutasteride |
| Rapid or severe AGA progression; willing to accept off-label use | Dutasteride (off-label); discuss with dermatologist |
| Concerned about side effects; prefer less aggressive DHT suppression | Finasteride 1 mg (lower DHT suppression = potentially less risk) |
| Needing a drug with shortest half-life for reversibility | Finasteride (clears in days vs. dutasteride’s weeks-long washout) |
Key Practical Differences
Half-life matters for discontinuation: Finasteride’s short half-life (~6 hours) means DHT levels recover within days of stopping. Dutasteride’s very long half-life (~5 weeks) means serum dutasteride persists for months after the last dose, and DHT suppression continues for 4–6 months after stopping. This has implications for men who want to trial a drug, stop it, or father children — stopping dutasteride does not rapidly clear the drug as stopping finasteride does.
Fertility: Both finasteride and dutasteride reduce ejaculate volume and may affect semen parameters (sperm count, motility). Dutasteride’s longer persistence means its effects on semen persist longer after stopping. Men planning conception should discuss both drugs with a urologist.
Frequently Asked Questions
Can I switch from finasteride to dutasteride?
Yes, switching is possible and is done clinically in men who have had inadequate response to finasteride. Because dutasteride is off-label for AGA in the US, this requires a physician prescribing it off-label. You do not need to wean off finasteride before starting dutasteride. Some dermatologists will switch men who respond but progress on finasteride, or who are willing to accept greater DHT suppression for potentially better results.
Is dutasteride safe to use off-label for hair loss?
Dutasteride has a well-characterized safety profile from its approved BPH indication (Avodart). Its use for AGA is off-label in the US but supported by clinical trial data and approved in two countries for that indication. The main safety considerations are the same as finasteride — sexual side effects, potential PFS-type persistent effects, and teratogenicity (Pregnancy Category X) — with potentially higher rates due to greater DHT suppression. Discuss risks and benefits with a physician who can review your individual clinical profile.
About this page: Reviewed by [Reviewer Name, MD, Dermatology]. Efficacy data from Olsen et al. 2006 and Gubelin Harcha et al. 2018 meta-analysis. Last reviewed August 2026. Editorial policy.
Sources
- Olsen EA, et al. “The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.” J Am Acad Dermatol. 2006;55(6):1014–1023.
- Gubelin Harcha W, et al. “A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects.” J Am Acad Dermatol. 2014;70(3):489–498.
- Merck & Co. Propecia US Prescribing Information. 2022. GlaxoSmithKline. Avodart (dutasteride) US Prescribing Information. 2021.